Entities

Co-founder and director of ChronicleBio, supporting its work on therapies for complex chronic disease.

Chief scientific officer for translational biology at ChronicleBio, with experience in immunology and drug development.

Co-founder and executive chairman of ChronicleBio.

Co-founder and CEO of ChronicleBio, with a background in biobanking and precision medicine at Stanford and UCSF.

Head of platform and founding scientist at ChronicleBio, working on computational biology and longitudinal human biological data.

Georgia Needham is listed by Caravel Bio as Biotechnologist. The company's current team directory is the source for this role and original individual portrait.

Aidan Haney is listed by Caravel Bio as Biotechnology Engineer I. The company's current team directory is the source for this role and original individual portrait.

Arushi Kalia is listed by Caravel Bio as Senior Engineering Research Associate. The company's current team directory is the source for this role and original individual portrait.

Dana Merrick is listed by Caravel Bio as Founding Infrastructure Engineer. The company's current team directory is the source for this role and original individual portrait.

Rick Sayler is listed by Caravel Bio as Head of BioInorganic Engineering. The company's current team directory is the source for this role and original individual portrait.

Agneya Bhushan is listed by Caravel Bio as CINO. The company's current team directory is the source for this role and original individual portrait.

Michał Jastrzębski is listed by Caravel Bio as CTO. The company's current team directory is the source for this role and original individual portrait.

Emily Bowman is listed by Caravel Bio as CSO. The company's current team directory is the source for this role and original individual portrait.

Caravel Bio is a Portland, Oregon synthetic-biology company developing an integrated platform for protein discovery, engineering and delivery. It combines cell-free protein synthesis, bacterial spore display and high-throughput directed evolution to create robust industrial proteins and machine-learning training datasets. Research applications include enzyme-based carbon capture, biochemical manufacturing, DNA synthesis and animal health. Founder and CEO Trevor Nicks developed the underlying technology in research at Tufts University; its current official roster includes nine named team members. In October 2025, Caravel announced a $1.9 million pre-seed round from 2048 Ventures, The Venture Collective, Pioneer Fund and Portland Seed Fund, alongside an NSF CFIRE PRESENT award with an estimated total of $7.8 million supporting a collaborative project led by Caravel. Federal records distinguish that estimated award ceiling from $5,521,174 obligated as of the reviewed record. It also received a $275,000 NSF SBIR Phase I grant and a 2026 Phase II award estimated at $1,246,984, of which $311,746 was initially obligated. Caravel joined Shell GameChanger in July 2025 and disclosed funding for carbon-capture research in May 2026, with the amount undisclosed. Research collaborators and program participants are not automatically company employees or equity investors.

Trevor Nicks is listed by Caravel Bio as FOUNDER & CEO. The company's current team directory is the source for this role and original individual portrait.

Allison C. Waters is a neuroscience researcher at the Icahn School of Medicine at Mount Sinai and is explicitly identified by Neurosom as a Medical Advisor in its announcement of a second Parkinson's disease study using Sleep WISP. Her university research collaboration is distinct from the documented company advisory role.

Tess Pablo Teittinen is listed by Neurosom as Accounting Manager. The current company management directory and original named portrait establish this role. Historical image filenames are not used to infer a different present title.

Corin Tucker is listed by Neurosom as Chief Marketing Officer. The current company management directory and original named portrait establish this role. Historical image filenames are not used to infer a different present title.

Dee Dee Nunes is listed by Neurosom as Commercial Leader. The current company management directory and original named portrait establish this role. Historical image filenames are not used to infer a different present title.

Don Tucker is founder and CEO of Brain Electrophysiology Laboratory Company (BEL), founded in 2018, and Chairman and Chief Science Officer of affiliate Neurosom. Neurosom's SEC filing identifies him as Don M. Tucker. He founded Electrical Geodesics, Inc. in the early 1990s and is an emeritus University of Oregon psychology professor. The two affiliated companies publish distinct current role titles.

Phan Luu is Chief Science Officer of Brain Electrophysiology Laboratory Company (BEL) and Chief Technology Officer of affiliate Neurosom. He develops dense-array EEG and transcranial electrical stimulation technologies and previously held scientific and technical leadership roles at Electrical Geodesics and EGI Philips Neuro.

Viral Sheth is listed by Neurosom as CEO. The current company management directory and original named portrait establish this role. Historical image filenames are not used to infer a different present title.

Neurosom is a Eugene, Oregon neurotechnology company developing a precision brain-health platform combining EEG measurement, AI sleep-stage analysis and closed-loop transcranial electrical stimulation. Its wearable Sleep WISP is being studied for improving restorative sleep and related cognitive outcomes. NEAT, its neural-network EEG sleep-scoring software, has FDA 510(k) clearance under K250058, issued April 10, 2025 to affiliate Brain Electrophysiology Laboratory Company, LLC; this clearance is for the software's sleep-staging indications and does not establish approval of a dementia-prevention therapy. Neurosom was incorporated in Delaware on July 21, 2021 and licenses technology from BEL, a distinct affiliate under common control. Its public management team includes CEO Viral Sheth, Chairman and Chief Science Officer Don Tucker, CTO Phan Luu, Commercial Leader Dee Dee Nunes, CMO Corin Tucker and Accounting Manager Tess Pablo Teittinen. The company also explicitly identifies Mount Sinai researcher Allison C. Waters as a Medical Advisor. A January 6, 2026 release announced an oversubscribed bridge round approaching closing, led by Portland Seed Fund's Intrepid Oregon Fund with Loomis Family Trust, OEN Angel Syndicate and ONAMI participation. Its earlier Regulation Crowdfunding offering was conducted through Neurosom SPV, LLC. The January release's planned $5 million seed round is a fundraising target; a completed seed closing is not established by the reviewed sources. NIH grants for related sleep technology are awarded to BEL rather than directly to Neurosom.

Administrative board member at Brainlab. Former executive board member of the Federation of German Industries and a partner at FGS Global since April 2026.

Business lawyer and administrative board member at Brainlab. Partner at Argon Management and PMT Management, with earlier leadership roles at Swiss law firms.

Munich-based medical technology company founded in 1989 that develops software and systems for surgical navigation, treatment planning, radiosurgery and radiotherapy. Its technology combines medical imaging, patient-specific three-dimensional models, robotics, mixed reality and AI to support clinical workflows from diagnosis through treatment. It also makes strategic investments, including participation in Robeauté’s January 2025 Series A for neurosurgical microrobots.

Biotech entrepreneur and investor; co-founder of AYOXXA Biosystems and Proteona, and managing director of Springboard Health Ventures. Published as an EIC Fund portfolio-company board representative; ARTHEx Biotech independently names him as its EIC Fund board representative.

Co-founder and CEO of Robeauté. Robotics engineer and entrepreneur who previously founded Virtools, acquired by Dassault Systèmes.

Co-founder and COO of Robeauté, leading operations for its neurosurgical microrobot development.

Chief product officer at Robeauté, working on medical microrobotics. Distinct from the namesake CEO of Previa Medical.

Jim Huston co-founded Portland Seed Fund with Angela Jackson in 2011 and is currently listed as Managing Director Emeritus. His official biography describes earlier investment roles at Blueprint Ventures, Intel Capital and Exxon, and a focus on climate technology investing since 2022.

Shashi Jain is Venture Partner at Portland Seed Fund and Intrepid Oregon Fund, supporting early-stage deep technology businesses. His official biography describes earlier strategic innovation work at Intel involving IoT, healthcare, AI for space applications and blockchain, and community work in 3D printing and entrepreneurship.

Jenn Lynch is Managing Director of Portland Seed Fund, leading finance and investor relations. Her official biography identifies investing-partner roles with Funds II and III and an adviser role with Fund IV. She previously worked in software product management and Portland technology agencies.

Steve Eichenlaub is Managing Director of Portland Seed Fund IV and Intrepid Oregon Fund I. His official firm biography describes an association with Portland Seed Fund since 2014 as a limited partner in Funds II and III, and earlier executive and investing roles at M-SIX and Intel Capital.

Angela Jackson co-founded Portland Seed Fund in 2011 and is Managing Director of the firm and its deep-tech sister Intrepid Oregon Fund. Her official biography describes earlier roles at Portfolia, Emergent and Oregon's Angel Oregon program, and leadership of the Portland State Business Accelerator.

Tim Vogel is listed by Neurobiome as Partner. The company's own biography and original named portrait establish this affiliation; outside university positions are not assigned as company roles.

Kenton Hokanson is listed by Neurobiome as Partner. The company's own biography and original named portrait establish this affiliation; outside university positions are not assigned as company roles.

Maude David is listed by Neurobiome as Managing Partner. The company's own biography and original named portrait establish this affiliation; outside university positions are not assigned as company roles.

Neurobiome is an Oregon biotechnology company developing Gut-Brain Chip technology to study microbiome-derived compounds that affect neuronal activity. Its microfluidic platform uses dynamic flow and electrophysiology for high-throughput screening and aims to support discovery of neuroactive molecules relevant to gut-brain biology and neurodegenerative disease research. The company's website identifies the business as Neurobiome LLC and lists Maude David as Managing Partner, with Kenton Hokanson and Tim Vogel as Partners. These are company leadership titles. Neurobiome received backing through Elevate Capital's Oregon commercialization Innovation Gap Fund I, confirmed in the manager's October 2021 announcement and the current state portfolio. The reviewed sources do not disclose its investment amount, a complete employee roster or an approved treatment.

Zach Lerner is CTO and co-founder of Biomotum, developing assistive robotics for neurological mobility impairments. The current company directory identifies him as CTO; earlier investor and university materials use CSO. NIH awards identify Zachary Forest Lerner, while SEC filings use a different middle initial, so a longer legal name has not been inferred.

Ray Browning is CEO and co-founder of Biomotum, developing wearable robotic assistance for impaired walking. His current title and original portrait are published in the company's leadership directory.

Biomotum is a Portland, Oregon medical-device company developing wearable robotic assistance for people with neurological conditions affecting walking, including cerebral palsy and stroke. Its SPARK ankle-assistance technology combines wearable robotics with adaptive control to support gait rehabilitation; its current website describes international pilots and a 2026 launch. The official leadership directory lists co-founders Ray Browning as CEO and Zach Lerner as CTO. SEC filings identify Biomotum, Inc., incorporated in Delaware in 2019, and the earlier name Biomotum, LLC. Verified funding includes NIH SBIR and STTR research awards, private securities offerings and backing from Elevate Capital's Innovation Gap Fund I. The company was selected for an $80,000 BVC Impact investment in 2020 and an approximately $300,000 Angel Oregon life-sciences investment in 2022; those competition announcements may overlap its reported private offerings and are not added to an aggregate funding total. Its research grants are distinct from private investment. Clinical approval and a complete employee roster have not been established by the reviewed sources.

Vienna-based science venture initiative founded in 2025 by Speedinvest and TU Wien and subsequently expanded to Austria’s technical universities. It backs university and research spinouts at pre-seed, helping founders commercialize scientific intellectual property, assemble teams and prepare follow-on financing. Its focus includes deep tech, AI and software, climate and industrial technology, health technology, synthetic biology and biotechnology. The associated Noctua Science I fund is legally managed by Speedinvest GmbH.

Austrian software engineering and technology consultancy that builds and modernizes software systems for banks, insurers, industrial companies and public-sector organizations. Its teams work on software architecture, product delivery, cloud and platform engineering, and data and AI applications. It also participated as a corporate investor in Turn-Motion’s September 2026 pre-seed financing.

Vienna-based rehabilitation technology company developing automated multi-axis continuous carbon-fibre manufacturing for patient-specific orthotic and prosthetic sockets and exoskeleton components. Its TURN-FPEO software combines physics-informed AI with movement and load simulation to optimize fibre placement and generate production instructions. The company is developing and piloting this manufacturing system for orthotic workshops, rehabilitation providers and medical-device manufacturers.

Angel investor named in Turn-Motion’s September 2026 pre-seed financing announcement.

Angel investor named in Turn-Motion’s September 2026 pre-seed financing announcement.

Portfolio lead and managing director of Noctua Science Ventures. Previously supported TU Wien spinouts and co-founded Dataholics and HROS.

Angel investor named in Turn-Motion’s September 2026 pre-seed financing announcement.

Onsight Ventures is an Innsbruck venture capital firm investing in early-stage European deep-tech companies. Founded by Jasmin Güngör and Klaus Grössinger as a spin-off from the Hermann Hauser Family Office, it backs new computing architectures and semiconductors, quantum computing and sensing, artificial intelligence, cybersecurity, computational biology and synthetic biology. It supports technology companies with commercialisation, international networks and scaling, and is managed by Onsight Ventures Management GmbH.

Roofline is a German RWTH Aachen spin-off building compiler and runtime software for deploying AI models on edge devices. Its SDK translates models from frameworks such as PyTorch, TensorFlow and ONNX into executables optimised for different CPUs, GPUs and neural processors. The company develops a retargetable compiler based on MLIR and IREE, a system-on-chip inference runtime and performance tools so product and chip developers can deploy language, vision, audio and other models across heterogeneous hardware.

Synteny develops MANIFOLD, an AI and experimental biology platform for designing protein therapeutics. It combines sequence, structure and physics models with large-scale laboratory measurements of molecular binding to predict affinity, specificity and unwanted interactions, then tests AI-designed molecules in high-throughput assays. Its first therapeutic application is T-cell receptor T-cell engagers for solid tumours and immunology. The UK-headquartered company also has a US presence; these are research and drug-development programmes rather than marketed or approved treatments.

Heads discovery at Synteny. Previously led target identification and development work on Immunocore’s KIMMTRAK T-cell receptor therapy.

Heads autonomous AI at Synteny, working on systems for scientific exploration. His background includes UiPath, reinforcement learning, generative models and large language models.

Co-founder and chief scientific officer of Synteny. Leads a research laboratory at Cambridge’s Early Cancer Institute studying quantitative cancer evolution.

Leads protein-engineering AI at Synteny, with a focus on artificial intelligence for drug discovery.

Co-founder and CEO of Synteny. Previously co-headed Growth Equity at Generation Investment Management; studied computational biology at Cambridge and mathematics at Dartmouth.

Heads computational biology at Synteny, following a research career at Microsoft Research in biological computation.

Life-sciences and healthcare investor at Obvious with prior Verily and Northpond experience; studied biological sciences at Oxford and earned an MBA at Harvard.

Senior software engineer at Roofline. A different person from SHS Capital partner Tobias Fuchs, whose own biography and LinkedIn identity describe a finance and law career.

Kanth Gopalpur is listed by Elevate Capital as Advisor. The official firm biography is the source for this affiliation.

Stephen Marsh is listed by Elevate Capital as Advisor. The official firm biography is the source for this affiliation.

Barbara Johnson is listed by Elevate Capital as Executive Assistant. The official firm biography is the source for this affiliation.

Pam Gates is listed by Elevate Capital as Controller. The official firm biography is the source for this affiliation.

Raghu Raghavan is listed by Elevate Capital as Partner Emeritus. The official firm biography is the source for this affiliation.

Robin Jones is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Ketan Sampat is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Ana Chaud is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Chris Bright is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Randy Lund is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Michael Choi is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Jill Nelson is listed by Elevate Capital as Executive Partner. The official firm biography is the source for this affiliation.

Lateef Jackson is listed by Elevate Capital as Limited Partner. The official firm biography is the source for this affiliation.

Donn Dimond is listed by Elevate Capital as Limited Partner. The official firm biography is the source for this affiliation.

Doug Fieldhouse is listed by Elevate Capital as Limited Partner. The official firm biography is the source for this affiliation.

Tariq Q. Khan is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Supriya Rao is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Srivatsan Laxman is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Krishna Chittabathini is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Annu Navani is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Soumitra Sengupta is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Giovanni Magni is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Dipty Desai is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Allie Persitz is listed by Elevate Capital as Operating Partner. The official firm biography is the source for this affiliation.

Anu Shukla is listed by Elevate Capital as Venture Partner. The official firm biography is the source for this affiliation.

Brandon Ross is listed by Elevate Capital as Senior Associate-Analyst. The official firm biography is the source for this affiliation.

Vageesh Jha is listed by Elevate Capital as Associate (Fund Operations & Administration). The official firm biography is the source for this affiliation.

Ben Nahir is listed by Elevate Capital as Partner. The official firm biography is the source for this affiliation.

Kumar Sripadam is listed by Elevate Capital as General Partner. The official firm biography is the source for this affiliation.

Nitin Rai is listed by Elevate Capital as Founder & Managing Partner. The official firm biography is the source for this affiliation.

Elevate Capital is an Oregon venture capital firm founded in 2016 by Nitin Rai, with its current office in Beaverton. It invests in overlooked and underrepresented founders and supports early-stage technology, healthcare, life sciences, AI and research-driven deep-tech businesses. Its strategies include the Inclusive Fund, Capital Fund II, Business Oregon’s Innovation Gap Funds and the SSBCI Venture Direct program. The firm provides capital and mentorship from pre-seed through Series A, with check sizes varying by program. Its documented investments include Rewire AI, the Washington State University spinout developing computer vision for biomedical image analysis. The official directory includes investment and operating staff, venture and executive partners, limited partners, an emeritus partner, support staff and advisers; these roles are preserved separately. Elevate Capital is distinct from Elevate Ventures, BAM Elevate and other similarly named organizations.

John Harkness is the founder and CEO of Rewire AI, previously Rewire Neuro. He earned a behavioral-neuroscience doctorate at Oregon Health & Science University in 2015 and researched perineuronal nets at Washington State University Vancouver, where he developed Pipsqueak image-analysis software. His March 2025 legislative testimony confirms the founder and CEO role; older WSU materials describe an earlier co-founder and Chief Science Officer role.

Kristy Lawton is the scientific lead of Rewire AI and a neuroscience researcher. In Rewire’s November 2021 company article, she identifies herself as Chief Science Officer; the Coffin Lab’s alumni directory identifies her as Chief Scientific Officer of Rewire AI. She is an inventor named on the company’s adaptive machine-learning technology. A verified individual portrait was not located.

Rewire AI is a Portland, Oregon-based biomedical computer-vision company spun out of Washington State University. Previously branded Rewire Neuro and Rewire Neuroscience, it announced the Rewire AI name in April 2023; its current website identifies the business as Rewire Neuro, Inc. Its Polygon AI image-analysis software, previously Pipsqueak Pro, and Sightologist.ai inference engine automate cell and biomarker detection and quantification in microscopy images, with custom machine-learning models and integrations for research and diagnostic-device partners. Founder and CEO John Harkness trained in behavioral neuroscience; Kristy Lawton is its scientific lead. Partnerships include Neurescence for neuronal image analysis and eLabNext for laboratory workflow integration. Documented support includes NIH SBIR and STTR research grants, Business Oregon grants, an Angel Oregon Tech investment and pre-seed backing from Elevate Capital. NIH records identify the recipient under the earlier name Rewire Neuroscience, LLC, with John H. Harkness as principal investigator. These research awards are distinct from equity financing. Company releases describe a 2019 founding, while university materials document the earlier neuroscience startup and technology origins. The current public sources do not establish a complete employee roster or clinical approval for its software.

Farang is a Stockholm AI research company developing FX, a proprietary foundational AI architecture intended to generalise across reasoning, spatial problems, visual recognition, time-series forecasting and language. Its early research used a brain-inspired approach to forming responses before expressing them as text; the company now focuses on training and evaluating one architecture across multiple domains, with computational efficiency and generalisation as research objectives.

Phoenix Sustainable Investments is a UK investment and development group that builds and backs businesses in strategic land, housing, renewable energy, waste technology and research and development. Its work includes sustainable communities, low-carbon energy infrastructure and technology commercialisation. It also invests in healthcare, including leading funding for Upfront Diagnostics’ rapid stroke blood test.

Upfront Diagnostics, the trading name of Pockit Diagnostics Ltd., develops and commercialises LVOne, a portable finger-prick blood test that measures GFAP and D-dimer biomarkers to help clinicians identify large-vessel occlusion stroke at the point of care. It is designed for ambulance and emergency-care triage, helping route patients to hospitals that can provide thrombectomy. The company reports UKCA and CE marking and is piloting pre-hospital deployment with London Ambulance Service.

Founder of Farang, a Swedish foundational AI research company. The company describes his background as engineering, search, artificial intelligence and startup ventures.

Entrepreneur and former Klevu founder, named as an angel investor in Farang’s August2025 seed round.

Entrepreneur and former Klevu founder, named as an angel investor in Farang’s August2025 seed round.

Group Technical Director at Phoenix Sustainable Investments, overseeing technical strategy, due diligence, infrastructure planning and sustainable project delivery across the group. Joined the group in 2023.

Kiutra lists Wolfgang Neubert in its Board and advisors directory as its APEX Ventures representative. The directory does not specify a separate director or adviser title.

Barry Silverstein is listed by Luminate NY as Advisory Board Member.

Darius Sankey is listed by Luminate NY as Advisory Board Member.

David Heller is listed by Luminate NY as Advisory Board Member.

Don Golini is listed by Luminate NY as Chairman, Advisory Board.

Duncan Moore is listed by Luminate NY as Advisory Board Member.

Edward White is listed by Luminate NY as Advisory Board Member.

James Senall is listed by Luminate NY as Advisory Board Member.

Linda Smith is listed by Luminate NY as Advisory Board Member.

Marc Tricard is listed by Luminate NY as Advisory Board Member.

Michael Jackman is listed by Luminate NY as Advisory Board Member. Listed in Despierta’s combined advisors/select-LPs group, without an individual commitment or precise capacity. Its published biography describes Leidos healthcare operations and prior Ardan Equity, Mach7, GE Healthcare, Carestream and IBM work. These outside titles are undated source credentials, not newly asserted current positions.

Ryne P. Raffaelle is listed by Luminate NY as Advisory Board Member.

Harsh Yallapragada is listed by Luminate NY as Data Analyst (shared NextCorps staff).

Jenifer Bunis is listed by Luminate NY as Advisory Board Member.

Milton Chang is listed by Luminate NY as Advisory Board Member.

Stephen D. Fantone is listed by Luminate NY as Advisory Board Member.

Stu Elby is listed by Luminate NY as Advisory Board Member.

Thomas Brown is a Luminate advisory board member and director of the University of Rochester’s Institute of Optics. He is distinct from Anthropic co-founder Tom Brown.

Morgan Adams is listed by Luminate NY as Marketing and Content Coordinator (shared NextCorps staff).

Anjali Boriya is listed by Luminate NY as Finance Analyst.

Kate Leonard is listed by Luminate NY as Digital Marketing Manager (shared NextCorps staff).

Natalie Antal is listed by Luminate NY as Director, Sponsored Programs.

Holly Barrett is listed by Luminate NY as Marketing (shared NextCorps Chief Marketing Officer).

Veronica LoCurcio is listed by Luminate NY as Director of Operations.

Damon Diehl is listed by Luminate NY as Director of Technology Integration.

Sujatha Ramanujan is the former Managing Director and Chief Investment Officer of Luminate NY. On October 6, 2026, the University of Rochester announced her appointment as CEO of the NSF STELLAR Engine and her planned move to Luminate’s advisory board.

Luminate NY is a Rochester, New York-based accelerator and investment program launched in 2017 for startups commercializing optics, photonics, imaging and laser-enabled technologies. Administered by NextCorps and funded by Empire State Development, it supports deep-tech applications including machine vision, biophotonics, quantum technology, semiconductors, autonomous systems and healthcare. The program provides initial investment of up to USD100,000, currently structured as a convertible note, mentoring and access to industry and laboratory resources, with additional funding awarded through its annual competition. Its portfolio includes Neurescence, which received a USD100,000 initial investment through cohort two. As announced October 6, 2026, former Managing Director and Chief Investment Officer Sujatha Ramanujan is moving to the NSF STELLAR Engine and will join Luminate’s advisory board; Veronica LoCurcio and Damon Diehl continue to lead its operations and technology integration. The program reported USD26 million invested across 96 startups as of October 2026.

Roshni Christo joined Neurescence in 2020 as a Field Application Scientist. Bruker’s post-acquisition researcher profile identifies her as Senior Application Scientist for Multi-Region Miniscope Microscopy at Bruker. Her earlier work includes neuroscience research at Baylor College of Medicine.

Taufik Valiante is a Neurescence co-founder identified in Google’s accelerator story, which describes his input into the company’s epilepsy research direction. He is a University Health Network neuroscience researcher; his current operating role at the acquired company is not established.

Neurescence is a Toronto-based neuroscience technology company acquired by Bruker in 2022. It developed fiber-bundle miniature microscopes for simultaneous optical recording and stimulation across multiple brain or spinal-cord regions in freely behaving animals. Its Quartet and Chromatone systems support calcium imaging and optogenetics, while its research software incorporates machine learning for neuronal image analysis. Yasaman Soudagar, Sepideh Hashemi and Taufik Valiante are documented co-founders. Its original Canadian corporation was incorporated on August 18, 2014 and amalgamated into a corporation of the same name on November 30, 2022; Bruker’s acquisition announcement separately describes a 2015 founding. Neurescence received a USD100,000 Luminate accelerator investment through the second cohort selected in November 2018, as well as Canadian NRC research and youth-employment contributions. Bruker announced its acquisition agreement on November 14, 2022; subsequent Bruker materials confirm the acquisition, with financial terms undisclosed. The technology is for neuroscience research and preclinical applications.

Sepideh Hashemi is a co-founder of Neurescence. Google’s founder story describes her joining Yasaman Soudagar in 2018, bringing medical-device development and commercialization experience. Her current operating role following the Bruker acquisition is not established.

Yasaman Soudagar is a Neurescence co-founder and its former CEO. A physicist trained in experimental quantum optics, she helped develop multi-region miniscopes. Bruker’s post-acquisition researcher profile identifies her as Senior Director of Multi-Region Miniscope R&D at Bruker.

Atmos Ventures is a Warsaw-based deep-tech venture capital firm backing businesses built around scientific and engineering breakthroughs. Its focus spans AI, robotics and automation, quantum computing, infrastructure and cloud technology, and advanced hardware. The firm supports teams commercialising research into products, including technology for neurological biomarkers and other difficult technical applications.

Aether Biomedical develops bionic prosthetic hands and digital tools for upper-limb rehabilitation. Its Zeus multi-articulating hand uses biosignal processing to let users control grip and movement, while its software platform supports prosthesis configuration and clinical monitoring. The company was established in Poland in2018 and operates through regional teams and partners in Europe, the United States and India.

Abbas El Gamal is a Stanford electrical engineering researcher and co-founder of Inscopix, established in 2011 to commercialize the miniature microscope developed at Stanford.

Mark Schnitzer is a Stanford neuroscience and optical imaging researcher and scientific co-founder of Inscopix, established in 2011 to commercialize the miniature microscope developed at Stanford.

Keh-Yi Hong is listed in Inscopix’s public directory as General Manager, Asia Pacific Commercial Operations. The directory includes historical entries; current employment has not been independently confirmed.

Shanna Resendez is listed in Inscopix’s public directory as Senior Director, Customer Excellence. The directory includes historical entries; current employment has not been independently confirmed.

Shay Neufeld is listed in Inscopix’s public directory as Director, Data Products and Analytics. The directory includes historical entries; current employment has not been independently confirmed.

Sarah MacNamee is listed in Inscopix’s public directory as Senior Director, Sales, Western Markets. The directory includes historical entries; current employment has not been independently confirmed.

Jonathan Nassi is listed in Inscopix’s public directory as Senior Director, Translational Science. The directory includes historical entries; current employment has not been independently confirmed.

Michaela Mueller is listed in Inscopix’s public directory as Chief Financial Officer. The directory includes historical entries; current employment has not been independently confirmed.

Kunal Ghosh founded Inscopix in 2011 to commercialize the Stanford miniscope. He served as CEO, continued to lead the business after its acquisition by Bruker in 2022, and has since announced his departure from Bruker.

Solvemed develops smartphone-based quantitative pupillometry and AI analysis of eye biomarkers for neurological assessment and research. Its PuRe Pupillometer measures pupil size and light response to help clinicians record standardised neurological observations at the bedside, including in intensive care, stroke and emergency settings. The company also researches eye-based markers of fatigue and cognitive strain with academic partners.

DYNANIC develops FPGA firmware and software that turn programmable accelerator cards into SmartNICs for high-speed networking. Its platform offloads packet processing at speeds up to 400Gbps and exposes a standard DPDK interface, allowing customers to deploy network applications without developing FPGA logic themselves. The company is a Brno University of Technology spin-off, legally DynaNIC Semiconductors s.r.o., previously known as Brnologic.

Tensor Ventures is a deep-tech venture capital firm investing at seed and Series A in AI, quantum computing, computational biotechnology, developer tools, advanced computing and sustainable technology. It sources companies through university networks and technology specialists, and backs research spin-offs and startups in Europe and other markets. Its investments include programmable network hardware, antibody discovery, digital biomarkers and AI infrastructure.

AMADTEUS Technologies develops miniaturised and automated chemistry platforms for early drug discovery. It combines high-throughput synthesis and screening, acoustic nanolitre dispensing, multicomponent chemistry and computational methods to explore libraries of potential bioactive molecules while reducing reagent use and manual experimentation. The Hamburg company is a spin-off associated with Palacký University Olomouc and was co-founded within the IP Lab Ventures ecosystem. It has partnered with Accelerated Muscle Biotechnologies and Sarcometrics to apply accelerated discovery to cardiac and skeletal muscle therapies and supplements.

Biorea is an Ostrava-based Czech company commercialising technology from VŠB – Technical University of Ostrava that converts contaminated organic waste, including wood and plastics, into usable carbon materials. The process uses hydrothermal treatment followed by activation, neutralisation and drying, with potential applications in energy, electrical engineering and other industries. Biorea was co-founded within the IP Lab Ventures ecosystem.

Chemist and founder of AMADTEUS Technologies, working on multicomponent chemistry, automated nanoscale synthesis and drug discovery.

Global Water Nanotechnologies (GWN) develops nano-iron materials and deployment systems for contaminated-water treatment. Its products under development include effervescent tablets, suspensions, pellets and tailored systems for heavy-metal removal and organic-pollutant degradation. The company works on pilots for industries such as electroplating, mining, chemical manufacturing and wastewater treatment. GWN was co-founded and incubated within the IP Lab Ventures ecosystem.

Preagon Biotech develops species-selective insecticide molecules intended to control pests and disease vectors while reducing effects on beneficial organisms. Its research combines insect endocrinology, structural and chemical biology, deep-learning cheminformatics, protein molecular dynamics and high-throughput chemical screening. The company was co-founded and incubated within the IP Lab Ventures ecosystem; its website describes research and development, rather than an approved or commercially proven safety claim.

Atomiver develops nitrogen-doped graphene materials for high-performance energy storage. Its SC-GN3 electrode material is designed for supercapacitors and related devices that combine high energy and power density. The company also explores applications of its materials in batteries and other technologies. It was incubated and co-founded by members of IP Lab Ventures and participated in the NATO DIANA accelerator; participation in the accelerator does not establish a venture funding round.

IP Lab Ventures is a Czech and Central European deep-tech venture platform that helps university and research teams commercialise intellectual property, establish spin-offs and develop their businesses. Its planned seed and early-stage fund focuses on AI applications, autonomous systems, robotics, biotechnology, cybersecurity, semiconductors and advanced manufacturing. Its partners also incubate companies in advanced materials, protein modelling, drug discovery, agricultural biotechnology and water treatment. IP Lab GP S.à r.l. is the Luxembourg general partner and intended manager of IP Lab Ventures Fund I; the website is published by IP Lab Holding s.r.o.

MendelFOLD develops protein structure and dynamics modelling software for biotechnology research. Its platform analyses folding pathways, binding sites and functional networks to help researchers study protein behaviour and design drugs and engineered proteins. Founded in November 2024, it was incubated and co-founded within the IP Lab Ventures ecosystem; investment by the planned IP Lab fund has not been confirmed.

Organic chemist and chemical biologist; founder and Chief Scientific Officer of MendelFOLD. Holds Ph.D., FRSC and CChem credentials. Distinct from the neuroscience executive Andrew Miller, chair of Progentos Therapeutics.

Ponderosa Ventures is Galvanize’s pre-seed and seed investment strategy for climate technology in food, agriculture, oceans, water and forestry. It invests globally, with a focus on the US and Europe, and targets initial checks of USD100,000–750,000. Its portfolio includes AI-powered soil carbon measurement, vision models for manufacturing, spatial AI for forestry and autonomous agricultural robotics. Evi Steyer is co-founder and general partner; Chloë Payne and Anthony Cortese are principals, and Galvanize CEO Katie Hall serves on the investment committee. Ponderosa participated in Coolant’s financing announced in October 2025.

Wicklow Capital is a US investment organization founded by Daniel Tierney. It combines venture capital investing with venture philanthropy, with stated interests in artificial intelligence, blockchain, climate and democracy. ISTA identified Wicklow as a seed investor in Syntropic Medical in April 2025. The same announcement described a EUR750,000 contribution to ISTA’s translational fellowship program and EUR300,000 intended for emerging startups. These program contributions do not disclose an investment amount for Syntropic Medical or the size of a Wicklow investment fund.

Immersive healthcare technology company developing virtual and mixed-reality platforms for clinicians and patients. Its software combines interactive therapeutic environments with tracking and data analysis for mental-health care, pain management, cognitive training and physical rehabilitation. It supplies tools for healthcare professionals and operates virtual-care services, with AI-assisted features designed to support treatment workflows and personalized care.

Isabel Jiménez Bernal is an investment professional at Asabys Partners, publicly promoted to Principal in2025. Augustine Therapeutics’ June2024 first SeriesA closing announcement named Isabel Jiménez of Asabys as a new board observer. Her full Asabys identity is corroborated by her own public promotion post and existing institutional affiliation; she is distinct from Isabel Jiménez at Biocross. The Augustine observer relationship is a dated appointment and does not establish a personal investment or current executive employment. Asabys’ current published biography confirms she is a Principal who joined in 2022, and currently serves as board observer at Augustine Therapeutics and Orikine Bio. She previously worked with Ysios Capital and in hemato-oncology and immunology at VHIO; she holds a medicine PhD from the Autonomous University of Barcelona, an immunology master’s and an ESADE Executive MBA.

Vijay Barathan is Optum Ventures global partner based in London. Previously he invested in digitalhealth and life sciences atCatapult, led healthcareIPcommercialisation investments and worked in healthcare investmentbanking atPeelHunt/PiperJaffray. He initially practisedNHSmedicine and trained atGuy’s,KingsandStThomas, with medical and developmental-neurobiology degrees. His existing XRHealth affiliation remains separate and preserved.

Solgate is a Klosterneuburg, Austria-based biotechnology company founded in 2020 as a CeMM and ISTA spinout. It develops drugs targeting solute carrier membrane proteins using cell-based screening, chemoproteomics and medicinal chemistry, with programs relevant to neurological, autoimmune and metabolic disorders. Ariel Bensimon leads the company as co-founder and CEO. Its first financing with ISTcube, now XISTA Science Ventures, and unnamed private investors was announced in February 2021. It has also received AWS and FFG research grants. Solgate retains its own platform and pipeline alongside a collaboration with Curie.Bio through the separate US venture Cellgate Therapeutics.

Neurolentech is an ISTA spinout based in Klosterneuburg, Austria. It provides patient-derived neuronal models and functional assays for neuroscience drug discovery, including epilepsy and autism. Its services combine electrophysiology, drug screening and transcriptional profiling across genetically diverse patient cohorts. It also supplies functional data for AI models in biology and neuroscience. Its founders include Carsten Pfeffer, Gaia Novarino and Christoph Bock. XISTA Science Ventures, then ISTcube, announced a seed investment in October 2021; ISTA subsequently reported a separate AWS Seedfinancing grant in 2022. Amounts were not disclosed in these sources.

Biotechnology company developing blood-based prognostic tests for neurodegenerative disease. Its MAP-AD test combines mitochondrial DNA methylation biomarkers, sequencing and machine learning with clinical risk factors to estimate whether a patient with mild cognitive impairment will progress to Alzheimer’s dementia. The test supports patient stratification and clinical-trial selection. MAP-AD obtained CE-IVDR marking in 2025; the company also operates a CAP-accredited, CLIA-certified laboratory.

Spanish venture capital manager, legally Clave Mayor, that finances technology transfer, early-stage technology businesses and industrial SMEs. It works with universities, research centers and corporate partners to commercialize scientific developments, with strategies covering healthcare, agrifood, industrial technology and renewable energy. Its healthcare investments include blood-based Alzheimer’s prognosis, while its Mondragón funds support businesses of strategic interest to the cooperative group.

Medical-device company developing wearable EEG systems and artificial-intelligence algorithms for neurological care. Its mjn-SERAS device records brain activity through a discreet earpiece and assesses seizure risk to warn people with epilepsy and help them take protective action. The company reports CE certification as a Class IIa medical device. It also researches portable EEG and AI tools for earlier Alzheimer’s disease assessment through its DREAMER and mjn-BRiAN projects.

Artificial intelligence researcher and advisory board member at MJN Neuro.

Clinical advisory board member of ProMIS Neurosciences and board observer at ADmit Therapeutics. Physician and co-founder of the Alzheimer’s Drug Discovery Foundation with expertise in dementia research and therapeutic development. Howard Fillit is Co-Founder and Chief Science Officer Emeritus at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Emeritus; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Syntropic Medical is a Klosterneuburg, Austria-based medical device company spun out of the Institute of Science and Technology Austria. It develops HAVEN, an investigational headset that delivers visual neuromodulation for research into major depressive disorder and neuroplasticity. Its founders are Mark Caffrey, Jack O’Keeffe, Alessandro Venturino and Sandra Siegert. The company announced undisclosed seven-figure early financing from XISTA Science Ventures and Austria Wirtschaftsservice in April 2024, followed by a separate EUR1.1 million FFG research grant in July 2024. HAVEN has not received regulatory clearance or approval.

Biotechnology company developing blood-based biomarker assays for neurodegenerative disease assessment. Its e4Risk test detects the ApoE4 protein, a genetic-risk-associated biomarker relevant to Alzheimer’s disease, using routine laboratory analyzers. It also develops quantitative ApoE4 and other dementia biomarker tests. Test results support evaluation alongside other clinical information and do not establish an Alzheimer’s diagnosis on their own.

Applied-neuroscience company developing portable EEG screening tools and NeuroAI algorithms that analyze brain activity. Its CogniScore service combines an approximately eight-minute EEG recording with cloud-based analysis to assess cognitive health and flag possible decline, supporting earlier follow-up for dementia risk. The screening service supports clinical assessment rather than providing a standalone diagnosis.

Barcelona-based impact venture capital firm investing in early-stage businesses that improve health and reduce environmental harm. Its strategies cover healthy aging, children’s health and the climate transition, including medical technology, digital healthcare and low-carbon industrial systems. It manages the BSocial Impact funds and Montana, a dedicated pediatric-health fund investing worldwide.

Research assistant at Biocross, a developer of blood-based biomarker assays for neurodegenerative diseases.